全球感染性疾病治疗市场分析报告.ppt

marketresearchreport infectiousdiseasetreatments globalmarkets phm061a peggylehr projectanalyst bccresearch 35walnutstreet wellesley ma02481 phone 866 285 7215 sales webaddress e mail sales isbn 1 59623 590 x ii phm061a infectiousdiseasetreatments globalmarkets tableofcontents aboutbcc bccresearchisaleadinginformationresourceproducinghigh qualitymarketresearchreports newsletters andconferences bcc sinformationproductsexploremajormarket economic scientific andtechnologicaldevelopmentsforbusinessleadersinindustrial pharmaceutical andhightechnologyorganizations industryanalysisandmarketforecastsforadvancedmaterials high techsystemsandcomponents nanotechnologyandnovelprocessingmethodsareattheforefrontofthecompany sexpertise formorethan35years bcc smarketanalysishasprovidedbusinesseswiththeinsightneededtomakeintelligentandstrategicbusinessdecisions bccresearchisaunitofeliresearch whichisbasedindurham n c conditionsofpurchase thepurchaseoftheboundorelectroniccopyofthisreportconstitutesacontractualagreementbetweenbccresearchandthepurchaser thisreportisintendedforusesolelybythepersonwhomadethepurchase thereportanditscontentsarenottobemadeavailabletootherpersons autonomousdivisions foreignsubsidiariesofthesamecompany orothercompanies reproductionofanymaterialinthisreportisstrictlyforbiddenwithoutwrittenpermissionofthepublisher inturn bccresearchwillregardtheidentityofthereport spurchaserasconfidential additionalcopies additionalboundcopiesofthisreport intendedforusebytheoperatingdivisionforwhichthefirstcopyispurchased maybeobtainedfrombccatdiscountedprices additionalboundcopypricesdonotapplytoreportspurchasedforuseatseparatelocations licensesforuseofelectroniccopiesbyadditionalpersonsorlocationsareavailable pleasecallbccforpricing customanalyses bccprovidescustomresearchstudiestailoredtoourclients needsinareasrelatedtothesubjectresearchmaterial butperhapsnotcoveredindetailinthisreport pleasecontactbccregardingthetermsandconditionsofsuchservices disclaimer thispublicationprovidesinformativematerialofaprofessionalnature itdoesnotconstitutemanagerial legaloraccountingadvice norshoulditserveasacorporatepolicyguide laboratorymanualoranendorsementofanyproduct thisinformationisintendedtobeasaccurateaspossibleatthetimeofpublication butbccinc assumesnoresponsibilityforanylossesordamagesthatmightresultbecauseofrelianceonthismaterial copyright2009bybccresearchwellesley ma02481 reproductionofanymaterialinthisreportisstrictlyforbiddenwithoutexpresspermissionofthepublisher toreceiveacompletecatalogofbccstudies pleasevisitourw april2010 copyright bccresearch wellesley mausa web iii phm061a infectiousdiseasetreatments globalmarkets tableofcontents chapterone introduction 1studygoalsandobjectives 1reasonsfordoingthestudy 1scopeofreport 2intendedaudience 2methodologiesandinformationsources 2analystcredentials 2relatedbccreports 2bcconlineservices 3disclaimer 3chaptertwo summary 4summary 4summarytableglobalmarketforinfectiousdiseasetreatments through2014 billions 5summaryfigureglobalmarketforinfectiousdiseasetreatments 2008 2014 billions 5chapterthree overview 6 table1selectedmajorinfectiousdiseases worldwide 2006 numberofcases annually 6table1 continued 7historicalimpactofinfectiousdiseases 7linkinginfectiousdiseasetocancer 8transmissionofinfectiousdiseases 8treatmentsforinfectiousdiseases 8prevention 8vaccination 9figure1percentofpreventablechildhooddeaths withvaccination 2002 9figure1 continued 10table2majormanufacturersofvaccinesfor infectiousdiseases 2008 10 table3estimatedvaccinesalesforinfectious diseases bymanufacturer 2008 millions 11 table4projectedsalesofvaccinestotreatinfectiousdiseasesworldwide through2014 billions 12table5selectedtreatmentmodalities bydiseaseandtypeofproduct 12 monitoringandsurveillance 13 copyright bccresearch wellesley mausa web iv phm061a infectiousdiseasetreatments globalmarkets tableofcontents currentimpactofinfectiousdiseases 13table6top10causesofdeath byincomegroup 2004 13table6 continued 14 antibiotic resistantorganisms 14implicationsofclimate changeoninfectiousdiseases 14keydriversofinfectiousdiseaseproductmarket 15keyobstaclesintheinfectiousdiseaseproduct market 15opportunitiestofightinfectiousdiseases 16opportunitiestofight continued 17chapterfour theglobalstateofinfectiousdisease controlandtreatment 18factorsintheemergenceofinfections 18humandemographicsandbehavior 18technology 18economicdevelopmentandlanduse 19internationaltravel 19microbialadaptation 19table7historyofantibioticdiscoveryandapproval 20 publichealthmeasures 20globalimplicationsofinfectiousdiseases 20regionaltrends 21 sub saharanafrica 21asiaandthepacific 21theformersovietunionandeasterneurope 21latinamerica 21middleeastandnorthafrica 21westerneurope 22globaleconomic social andpoliticalimpact 22economiccosts 22socialcosts 23politicalimpact 23implicationsofinfectiousdiseaseintheu s 23hiv aids 23hepatitisc 24tuberculosis 24influenza 24antibiotic resistantpathogens 24food borneillnesses 24 copyright bccresearch wellesley mausa web v phm061a infectiousdiseasetreatments globalmarkets tableofcontents infectiousdiseasesacquiredoutsideoftheu s 25emerginginfectiousdiseases 25emergingbacterialinfectiousdiseases 25emergingviralinfectiousdiseases 25metapneumoviruses 26henipavirus nipah hendra 26priondisease 26creatingtreatmentsforinfectiousdisease 27creatingdrugtreatments 27table8processofcreatingdrugtreatments 27table8 continued 28 creatingvaccines 29creatingvaccines continued 30table9topfivevaccine producingcompanies 2009 31 acquisitionsamongmanufacturersof infectiousdiseaseproducts 31table10selectedacquisitionsamonginfectious diseasedrugandvaccinemanufacturers 2006 2010 31table10 continued 32chapterfive bacterialinfectiousdiseases 33 table11selectedbacterialinfectiousdiseasesand thenumberofcasesinhumans 33table11 continued 34table12projectedmarketforantibacterial treatmentsthrough2014 millions 34theglobalantibacterialdrugmarket 35treatments 35 figure2leadingmanufacturersofantibacterial drugs withapproximatemarketshare 2008 35figure2 continued 36table13majormanufacturersofantibacterialsandtheirproducts 2009 36majorinfectiousbacterialdiseases 37bacterialdiarrhealdiseases 37cholera 37 frequency 37treatment 38clostridiumdifficile 38 treatmentsunderdevelopment 38campylobacter 39 copyright bccresearch wellesley mausa web vi phm061a infectiousdiseasetreatments globalmarkets tableofcontents treatment 39emergingfood borne water borneillnesses 39 table14currentlyavailabletreatmentsfor salmonellaandtheirmanufacturers 40 haemophilusinfluenzaeb hib 41vaccination 41table15projectedmarketforhibvaccine through 2014 millions 42 pneumonia 42currenttreatment 42vaccines 42table16projectedrevenuesfromvaccinesandmedicationstotreatpneumonia through2014 millions 43 sexuallytransmitteddiseases 43chlamydia 43table17primaryantibioticstotreatchlamydia 44 emergingtreatment 44gonorrhea 44table18primaryantibioticstotreatgonorrhea 45 emergingtreatment 45syphilis 45chancroid 46staphylococcalinfections 46 emergingtreatments 47 dalbavancin 47telavancin 47oritavancin 47ceftobiprole 48ceftaroline 48tuberculosis 48table19numberofcasesoftbannually bycountry 2007 49 frequency 49 unitedstates 49europeanregion 50drug resistantstrains 50currenttreatments 50table20projectedglobalrevenuesfortbdrugs through2014 millions 51 copyright bccresearch wellesley mausa web vii phm061a infectiousdiseasetreatments globalmarkets tableofcontents table21currentlyavailabletreatmentsfortbandtheirmanufacturers 51 emergingtreatments 51urinarytractinfections 52table22currentlyavailabletreatmentsforutisandtheirmanufacturers 53 emergingtreatments 53 bacterialinterference 53bacteriophagetherapy 53 bacteriophagetherapy continued 54bacterialvaccines 55 cationicpeptides 55cyclicd l a peptides 56chaptersix fungalinfectiousdiseases 57opportunisticfungalinfections 57primaryfungalinfections 57fungalinfectiousdiseases 58table23projectedcostofantifungalagentstotreatfungalinfections through2014 billions 58 figure3marketshareofcompaniesinvolvedinthe treatmentoffungalinfections 2009 59 candidiasis 59causesofcandidiasis 60frequency 60treatment 61table24currentmedicationsforcandidiasis 2009 61table24 continued 62 futuremarket 62aspergillosis 62table25currentmedicationsforaspergillosis 2009 63 coccidioidomycosis 63 frequency 63treatment 64 table26currentmedicationsforcoccidiodomycosis 2009 64 cryptococcosis 64 frequency 65treatment 65table27currentmedicationsforcryptococcosis 2009 65 mucormycosis 65 copyright bccresearch wellesley mausa web viii phm061a infectiousdiseasetreatments globalmarkets tableofcontents frequency 66treatment 66table28currentmedicationsformucormycosis 2009 66 paracoccidioidomycosis 67 frequency 67treatment 67 table29currentmedicationsfor paracoccidioidomycosis 2009 67 pneumocystiscarinii 68frequency 68treatment 68 table30currentmedicationsforpneumocystiscarnii 2009 69sporotyrichosis 69 treatment 69table31currentmedicationsforsporotyrichosis 2009 69 trichosporoninfections 70 frequency 70treatment 70table32currentmedicationsfortrichosporon infections 2009 70zygomycosis 71 frequency 71treatment 71table33currentmedicationsforzygomycosis 2009 71chapterseven viralinfectiousdisease 72majordiseases 72researchfunding 72table34globalprojectionsforviralinfectious diseasetreatments through2014 millions 73hiv aids 73 table35projectedglobalmarketforhivdrugs through2014 millions 74shiftingpriorities 74table3610leadingglobalhivmanufacturers 2010 74figure4marketsharefortopmanufacturersofhivtreatments 2009 75 emergingtreatments 76 gileadsciences 76merck 76 copyright bccresearch wellesley mausa web ix phm061a infectiousdiseasetreatments globalmarkets tableofcontents viivhealthcare 76tibotec 76 tmc278 77commonpediatricviralinfections 77poliomyelitis 77diphtheria tetanus pertussis dtp 78table37projectionsfordtp polio hibcombination vaccinesales through2014 millions 79 measles mumps rubella 79measles 79mumps 80rubella 80 table38projectedglobalrevenuesfrommmrvaccine through2014 millions 81croup 81otitismedia earinfections 81 causesofotitismedia 82treatment 82table39projectedcostsofotitismediatreatments through2014 millions 82 pharmacologicalintervention 82surgicalintervention 83table40globalsurgicalcostsformyringotomyin pediatricpatients through2014 millions 83 table41globalsurgicalcostsfor tonsillectomy adenoidectomyinpediatricpatients through2014 millions 84influenza 84influenzatreatments 85table42projectedglobalmarketforinfluenza treatments through2014 millions 85 figure5estimatedmarketshareofcompaniesin influenzatreatmentmarket 2009 86 emergingtreatments 86hepatitis 87table43hepatitischaracteristics bytype 87table43 continued 88table44vaccinesandmedicationsforthetreatmentofhepatitis 2010 88table44 continued 89 copyright bccresearch wellesley mausa web x phm061a infectiousdiseasetreatments globalmarkets tableofcontents table45projectedmarketforhepatitismedicationsandvaccines through2014 millions 90 hepatitisa 90 table46projectedrevenuefromhepatitisavaccinationandtreatments through2014 millions 91 hepatitisb 91 table47projectedrevenuefromhepatitisbvaccinationandtreatments through2014 millions 92 emergingtreatments 92hepatitisc 92 table48projectedrevenuefromhepatitisc treatments through2014 millions 93figure6marketsharesforhepatitisctreatments 2010 93figure6 continued 94 emergingtreatments 94herpesviruses 94table49herpesvirusesthatinfecthumans 94table50projectedmarketforherpessimplexvirus medications through2014 millions 95 herpessimplexvirustype1 hsv 1 95herpessimplexvirustype2 hsv 2 95prevalence 96emergingtreatment 96 chiron 96glaxosmithkline 97xenova glaxosmithkline 97avantimmunotherapeutics 97epstein barrvirus 98humanherpesvirus6 98humanherpesvirus8 98emergingherpestreatments 98nanoviricides inc 98cytogenix 99alnylampharmaceuticals inc 99varicellaviruses 99chickenpox 99shingles 100 copyright bccresearch wellesley mausa web xi phm061a infectiousdiseasetreatments globalmarkets tableofcontents table51projectedmarketforvaricellavaccines through2014 millions 101enteroviruses 101coxsackieviruses 101creutzfeldt jakobdisease cjd 102emergingtreatments 102 quinacrine 102pentosanpolysulphate pps 103opportunisticviralinfections 103cytomegalovirus 103 currenttreatments 104table52currenttreatmentoptionsforcmv 2009 104 kaposi ssarcoma ks 104hemorrhagicfevers 105arenaviruses 106bunyaviruses 106filoviruses 106flaviviruses 107 frequency 107currenttreatment 108humanpapillomavirus hpv 108treatment 108 table53projectedmarketforhpvtreatments through2014 millions 109 emergingtreatments 109upperrespiratoryviruses 109commoncold 109sinusitosis 110respiratorysyncytialvirus rsv 110table54currenttreatmentsforrsv 111table55projectedmarketforrsvtreatments through2014 millions 111 emergingtreatments 112 arrowtherapeutics 112alnylampharmaceuticals 112astrazeneca medimmune 112rotavirus 113globalimpact 114treatments 114rotateq 114rotarix 114 copyright bccresearch wellesley mausa web xii phm061a infectiousdiseasetreatments globalmarkets tableofcontents table56globalrevenuesforpediatricrotavirus vaccines through2014 millions 115 table57globalrotavirusvaccinesales by manufacturer 2008 millions 115chaptereight parasiticinfectiousdisease 116causesofparasiticdisease 116malaria 116 table58projectedglobalrevenuesformalarialpreventionandtreatmentmeasures through2014 millions 117 causesofmalaria 118malarialtreatments 118table59availabledrugsforthetreatmentofmalaria 2009 118 currenttreatments 119table60projectedglobalrevenuefrommalarial treatments through2014 millions 119 evolvingtreatments 119 glaxosmithkline 120novartis 120pfizer 120sanofi aventis 120sigma tau 120mosquitonetting 120table61mosquitonettingdistributed 2006 2008 121table62projectedsalesofmosquitonettingto globalreliefagencies through2014 millions 121neglectedtropicaldiseases 122 table63numberofannualinfectionsfrom leishmaniasis onochocerciasis andschistomiasis 122 table64availabletreatmentsforthemostcommonneglectedtropicaldiseases 123 leishmaniasis 123currenttreatment 124emergingtreatments 124onochocerciasis 124 treatment 125schistomiasis 125treatment 126trypanosomiasis 127 copyright bccresearch wellesley mausa web xiii phm061a infectiousdiseasetreatments globalmarkets tableofcontents africantrypanosomiasis 127chagasdisease 127treatment 127evolvingtreatments 128 table65availabledrugsforthetreatmentof trypanosomiasis 2009 129 lymphaticfiliariasis 129 treatment 130dengue 130 opportunitiesfortreatmentsforparasitic infectiousdiseases 130malaria 130 syntheticartemisinin 131eurartesim 131coartempediatricdispersibletablet 132pyramax 132phaseiprojects 132 tafenoquine 132artemisone 133preclinicalinvestigations 133 oz439 133mk4815 134mirincamycin 134dengue 134 clonetechnology 135nucleotidedeletion 135otherapproaches 136schistosomiasis 136onchocerciasis 136chapternine patentanalysis 137patentanalysis 137 table66infectiousdiseasetreatmentpatents by company yearfiled anddisease 2000 2010 138table66 continued 139table66 continued 140table66 continued 141table67infectiousdiseasetreatmentpatentsissued betweenjanuary2000andjanuary2010 bymajor company 142 copyright bccresearch wellesley mausa web xiv phm061a infectiousdiseasetreatments globalmarkets tableofcontents table68infectiousdiseasetreatmentpatents by country 2000 2010 143 table69patentsissuedfortreatmentofbacterial disease 2000 2010 143 table70patentsissuedfortreatmentoffungal disease january2000 january2010 144table71patentsissuedfortreatmentofviraldisease january2000 january2010 144 table72patentsissuedfortreatmentofparasitic disease january2000 january2010 145chapterten companydirectory 146amyrisbiotechnologies 146businessoverview 146alnylampharmaceuticals 146businessoverview 146financials 147products 147arscientific 147businessoverview 147financials 147products 148astrazeneca 148businessoverview 148financials 148products 149baxterinternational inc 149businessoverview 149financials 149products 150bristol myerssquibb 150businessoverview 150financials 150products 151cipla ltd 151businessoverview 151financials 151products 151crucelln v 152businessoverview 152financials 153 copyright bccresearch wellesley mausa web xv phm061a infectiousdiseasetreatments globalmarkets tableofcontents products 153cubistpharmaceuticals 154businessoverview 154financials 154products 155gileadsciences inc 155businessoverview 155financials 155products 156otherproducts 157glaxosmithkline 158businessoverview 158financials 158products 159hollypharmaceuticals 160businessoverview 160financials 160products 160ipcalaboratories 160businessoverview 161financials 161products 161johnson johnson 161businessoverview 161financials 162products 162mangalamdrugs organics ltd 163businessoverview 163financials 163products 163merck co 164businessoverview 164financials 164products 165novartisinternationalag 165businessoverview 165financials 166products 166pfizer 167businessoverview 167financials 167 copyright bccresearch wellesley mausa web xvi phm061a infectiousdiseasetreatments globalmarkets tableofcontents products 168pidistandard 169businessoverview 169financial 169products 170roche 170businessoverview 170financials 170products 170sanofi aventis 171sanofipasteur 171businessoverview 171financials 172products 173solvaypharmaceuticalss a 173businessoverview 174financials 174products 175vertexpharmaceuticals 175businessoverview 175financials 175products 176wyethpharmaceuticals pfizer inc 176businessoverview 176financials 177products 177 copyright bccresearch wellesley mausa web xvii phm061a infectiousdiseasetreatments globalmarkets listoftables summarytableglobalmarketforinfectiousdisease treatments through2014 billions 5table1selectedmajorinfectiousdiseases worldwide 2006 numberofcases annually 6table2majormanufacturersofvaccinesforinfectiousdiseases 2008 10table3estimatedvaccinesalesforinfectiousdiseases bymanufacturer 2008 millions 11table4projectedsalesofvaccinestotreatinfectiousdiseasesworldwide through2014 billions 12table5selectedtreatmentmodalities bydiseaseandtypeofproduct 12table6top10causesofdeath byincomegroup 2004 13table7history